Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Launched by NATIONWIDE CHILDREN'S HOSPITAL · Mar 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a medication called lorlatinib to see how well it works in treating children who have newly diagnosed high-grade gliomas, which are aggressive brain tumors. Specifically, the trial focuses on tumors that have changes in certain genes called ALK or ROS1. The study aims to find out how effective lorlatinib is when used either alongside chemotherapy or after radiation therapy.

To be eligible for this trial, children aged 1 to 21 years old with specific types of high-grade gliomas are invited to participate. They must have their tumor tested to confirm the presence of ALK or ROS1 gene changes. Participants will receive close monitoring to ensure the treatment is safe and to evaluate how well the medication works. It's important to note that this trial is still in the early phases and is not yet recruiting participants. Families should also be aware that certain medical conditions or previous treatments may affect eligibility, so a thorough review will be conducted before enrollment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment on TarGeT-SCR.
• 2. Diagnosis:
• • Patients with newly diagnosed high-grade glioma (HGG), including diffuse intrinsic pontine gliomas (DIPG), whose tumors harbor an ALK or ROS-1 fusion alteration are eligible. Patients must have had histologically verified high-grade glioma from diagnostic biopsy or resection. For the diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO Grade 2-4. All other HGGs must be Grade 3 or 4.
• 3. Disease Status:
• • Patients with disseminated DIPG or HGG are eligible only if the patient is to receive chemotherapy only, i.e. no craniospinal RT is intended to be given. MRI of spine must be performed if disseminated disease is suspected clinically by the treating physicians. Patients with primary spinal tumors are eligible only if the patient is to receive either chemotherapy or focal radiation therapy, i.e., no craniospinal RT is intended to be given. Patients with leptomeningeal disease only, with no definitive identifiable primary tumor, and documented ALK or ROS-1 fusion, must be discussed with the Study Chair on a case-by-case basis.
• 4. Performance Level:
• • Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
• 5. Prior Therapy:
• • Patients must not have received any prior anti-cancer chemotherapy.
• • Prior use of corticosteroids is allowed (see below Exclusion Criteria)
• 6. Organ Function Requirements 6.1 Adequate Bone Marrow Function Defined as:
• • Peripheral absolute neutrophil count (ANC) ≥ 1000/μL
• • Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
• * Hemoglobin \>8 g/dL (may receive transfusions) 6.2 Adequate Renal Function Defined as:
• * Serum creatinine within normal institutional limits OR Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 6.3 Adequate Liver Function Defined as:
• • Total bilirubin ≤ 2 × institutional upper limit of normal
• • AST(aspartate aminotransferase)/ALT(alanine transaminase) ≤ 2.5 × institutional upper limit of normal 6.4 Adequate Pulmonary Function Defined as: Pulse oximetry \> 94% on room air if there is clinical indication for determination (e.g. dyspnea at rest).
• • 6.5Adequate Cardiac Function Defined as: QTc ≤ 470 msec (by Bazett formula) 6.6 Adequate Neurologic Function Defined as: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
• • 6.7 Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines
• Exclusion Criteria:
• • 1. Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
• • Females of reproductive potential must use an effective non-hormonal method of contraception, since lorlatinib can render hormonal contraceptives ineffective, during study treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential must use effective contraception during treatment with lorlatinib and for 3 months after the final dose.
• • 2. Concomitant Medications
• • Investigational Agents/Drugs: Patients who have previously received or are currently receiving another investigational drug are not eligible.
• • Anti-cancer Agents: Patients who have previously received or are currently receiving other anti-cancer agents, including chemotherapy, immunotherapy, monoclonal antibodies, biologic or targeted therapy, are not eligible
• • 3. Infection: Patients must not have any active, uncontrolled systemic bacterial, viral or fungal infection.
• • 4. Patients who have received prior solid organ transplantation are not eligible.
• • 5. Patients must not have malabsorption syndrome or other condition affecting oral absorption.
• • 6. Patients must not be receiving any treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor or inducer. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to treatment with loraltinib. Moderate inducers of CYP3A4 should be avoided
• • 7. Avoid concomitant use of lorlatinib with certain CYP3A substrates, for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with approved product labeling.
• • 8. P-glycoprotein (P-gp) substrates: Lorlatinib is considered a moderate P-gp inducer. Co-administration of lorlatinib with P-gp substrates including but not limited to digoxin should be avoided as the concentration of these drugs may be reduced by lorlatinib.
• • 9. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
• • 10. Patients with a known personal history of acute or chronic severe psychiatric disorders or current history of suicidal ideation and history of suicide attempt.